Table 1.
Baseline characteristics of patients treated with nivolumab plus ipilimumab or the BRAF/MEK inhibitors in randomized controlled trials with advanced melanoma
| NIVO+IPI (CheckMate 067)6 ITT population (n = 314) |
NIVO+IPI (CheckMate 067),6BRAF-mutant patients (n = 103) |
DAB+TRAM (COMBI-d/v)8,21 (n = 56) |
ENCO+BINI (COLUMBUS)22, 23, 24 (n = 192) |
VEM+COBI (coBRIM)9,25 (n = 247) |
|
|---|---|---|---|---|---|
| ESS for CheckMate 067 | – | – | 91.68 | 93.81 | 91.69 |
| Age, % | |||||
| >55 years | 63.7 | 56.3 | 50.0 | – | – |
| >56 years | 62.1 | 54.4 | – | – | 50.0 |
| >57 years | 58.6 | 48.5 | – | 50.0 | – |
| Male, % | 65.6 | 62.1 | 56.8 | 60.0 | 59.0 |
| ECOG PS ≥1, % | 26.4 | 22.3 | 27.9 | 29.0 | 24.0 |
| M stage, % | |||||
| M1b | 22.6 | 13.6 | 18.5 | 18.0 | 16.0 |
| M1c | 58.9 | 58.3 | 64.5 | 64.0 | 59.0 |
| LDH > ULN, % | 36.3 | 32.0 | 34.7 | 29.0 | 46.0 |
DAB+TRAM, dabrafenib plus trametinib; ECOG PS, Eastern Cooperative Oncology Group performance status; ENCO+BINI, encorafenib plus binimetinib; ESS, effective sample size; ITT, intention-to-treat; LDH, lactate dehydrogenase; M stage, metastasis stage; NIVO+IPI, nivolumab plus ipilimumab; ULN, upper limit of normal; VEM+COBI, vemurafenib plus cobimetinib.